NASDAQ:CPIX Cumberland Pharmaceuticals (CPIX) Stock Price, News & Analysis $7.39 -0.12 (-1.60%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$7.42 +0.03 (+0.34%) As of 10/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cumberland Pharmaceuticals Stock (NASDAQ:CPIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CPIX alerts:Sign Up Key Stats Today's Range$7.28▼$7.7450-Day Range$6.29▼$8.9752-Week Range$1.85▼$9.28Volume22,629 shsAverage Volume37,973 shsMarket Capitalization$110.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, acquisition and commercialization of prescription products for hospital care, gastroenterology and other targeted therapeutic areas. The company’s business model emphasizes branded medicines that address specific clinical needs and are marketed primarily in the United States. Its product portfolio has included Acetadote (acetylcysteine injection), used in the treatment of acetaminophen poisoning; Caldolor (ibuprofen injection), an intravenous nonsteroidal anti-inflammatory drug for pain and fever; and Kristalose (lactulose), a prescription treatment for constipation. Cumberland has also marketed products such as Vaprisol, used to manage certain cases of low blood sodium, and Omeclamox-Pak, a treatment for Helicobacter pylori infection and associated duodenal ulcers. Founded in 1999, Cumberland has expanded its portfolio through internal development, licensing agreements and acquisitions. The company is led by A.J. Kazimi, its co-founder, chairman and chief executive officer. Cumberland’s products are distributed through its commercial operations and selected business partners, with its primary commercial focus on the U.S. healthcare market.AI Generated. May Contain Errors. Read More Cumberland Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreCPIX MarketRank™: Cumberland Pharmaceuticals scored higher than 5% of companies evaluated by MarketBeat, and ranked 869th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCumberland Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCumberland Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Cumberland Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cumberland Pharmaceuticals is -10.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cumberland Pharmaceuticals is -10.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCumberland Pharmaceuticals has a P/B Ratio of 4.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cumberland Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.91% of the float of Cumberland Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCumberland Pharmaceuticals has a short interest ratio ("days to cover") of 8.07.Change versus previous monthShort interest in Cumberland Pharmaceuticals has recently decreased by 8.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCumberland Pharmaceuticals does not currently pay a dividend.Dividend GrowthCumberland Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Cumberland Pharmaceuticals this week, compared to 2 articles on an average week. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cumberland Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders42.07% of the stock of Cumberland Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.51% of the stock of Cumberland Pharmaceuticals is held by institutions.Read more about Cumberland Pharmaceuticals' insider trading history. Receive CPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CPIX Stock News HeadlinesCumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Breaks Above 200-Day Moving Average - Should You Sell?October 2 at 2:21 AM | americanbankingnews.comCumberland Pharmaceuticals Updates Ifetroban DMD Trial TimelineAugust 28, 2026 | tipranks.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 3 at 1:00 AM | Banyan Hill Publishing (Ad)Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, OpportunityAugust 13, 2026 | seekingalpha.comCumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call TranscriptAugust 4, 2026 | seekingalpha.comCUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTSAugust 4, 2026 | prnewswire.comCUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTSJuly 28, 2026 | prnewswire.comCumberland Pharmaceuticals Announces Special Dividend, Share BuybackJuly 13, 2026 | tipranks.comSee More Headlines CPIX Stock Analysis - Frequently Asked Questions How have CPIX shares performed this year? Cumberland Pharmaceuticals' stock was trading at $3.98 on January 1st, 2026. Since then, CPIX shares have increased by 85.7% and is now trading at $7.39. How were Cumberland Pharmaceuticals' earnings last quarter? Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced its quarterly earnings results on Tuesday, August, 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.07. The specialty pharmaceutical company had revenue of $0.17 million for the quarter, compared to analyst estimates of $8.50 million. Cumberland Pharmaceuticals had a negative trailing twelve-month return on equity of 28.81% and a negative net margin of 34.40%. Read the conference call transcript. How do I buy shares of Cumberland Pharmaceuticals? Shares of CPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cumberland Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cumberland Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), ExxonMobil (XOM), Netflix (NFLX) and Intel (INTC). Company Calendar Record date for 7/31 Dividend7/23/2026Dividend Payable7/31/2026Last Earnings8/04/2026Today10/03/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CPIX's financial health is in the Green zone, according to TradeSmith. CPIX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CPIX CIK1087294 Webwww.cumberlandpharma.com Phone(615) 255-0068Fax615-255-0094Employees93Year Founded1999Profitability EPS (Trailing Twelve Months)($0.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.84 million Net Margins-34.40% Pretax Margin-23.38% Return on Equity-28.81% Return on Assets-9.25% Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.96 Sales & Book Value Annual Sales$44.52 million Price / Sales2.49 Cash Flow$0.36 per share Price / Cash Flow20.48 Book Value$1.64 per share Price / Book4.51Miscellaneous Outstanding Shares14,980,000Free Float8,680,000Market Cap$110.70 million OptionableOptionable Beta0.06 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CPIX) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cumberland Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cumberland Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
